Rabusertib

N/A

Report date: 2026/05/20 20:02:01
NME

Base Information

Drug NameRabusertib
Drug Alias Namerabusertibum雷布舍替雷布色替IC-83LY-2603618
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCheckpoint kinase 1 inhibitors
TargetsCheckpoint kinase 1
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungPancreatic Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesTaiwanRomania +[10] 
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesArray BiopharmaEli Lilly And Company
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesEli Lilly And Company
Active IndicationsN/A
Inactive IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungPancreatic Neoplasms +[4] 

Other Information

ATC CodeN/A
Related LinksKEGG